Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies

a technology of sulfatase and deficiency, applied in the direction of enzymology, drug composition, metabolic disorders, etc., can solve the problems of hampered efforts to identify this gene(s) and achieve the effect of increasing the c-formylglycine generating activity

Inactive Publication Date: 2013-01-31
SHIRE HUMAN GENETIC THERAPIES INC
View PDF3 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a new gene called FGE, which is responsible for a rare metabolic disorder called Multiple Sulfatase Deficiency (MSD). The invention provides methods for diagnosing and treating this disorder by identifying and manipulating the FGE gene. The patent also includes nucleic acid molecules, polypeptides, and cells expressing activated forms of the FGE gene. The technical effects of the invention include the development of new tools for diagnosis and treatment of MSD, as well as new insights into the function of the FGE gene.

Problems solved by technology

In spite of intense biological and medical interest, efforts aimed at the identification of this gene(s) have been hampered by the rarity of MSD patients and consequent lack of suitable familial cases to perform genetic mapping.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
  • Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
  • Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Multiple Sulfatase Deficiency is Caused by Mutations in the Gene Encoding the Human Cα-Formylglycine Generating Enzyme (FGE)

Experimental Procedures

Materials and Methods

In Vitro Assay for FGE

[0300]For monitoring the activity of FGE, the N-acetylated and C-amidated 23mer peptide P23 (MTDFYVPVSLCTPSRAALLTGRS) (SEQ ID NO:33) was used as substrate. The conversion of the Cysteine residue in position 11 to FGly was monitored by MALDI-TOF mass spectrometry. A 6 μM stock solution of P23 in 30% acetonitrile and 0.1% trifluoroacetic acid (TFA) was prepared. Under standard conditions 6 pmol of P23 were incubated at 37° C. with up to 10 μl enzyme in a final volume of 30 μl 50 mM Tris / HCl, pH 9.0, containing 67 mM NaCl, 15 μM CaCl2, 2 mM DTT, and 0.33 mg / ml bovine serum albumin. To stop the enzyme reaction 1.5 μl 10% TFA were added. P23 then was bound to ZipTip C18 (Millipore), washed with 0.1% TFA and eluted in 3 μl 50% acetonitrile, 0.1% TFA. 0.5 μl of the eluate was mixed with 0.5 μl of matri...

example 2

[0324]The Human FGE Gene Defines a New Gene Family Modifying Sulfatases which is Conserved from Prokaryotes to Eukaryotes

Bioinformatics

[0325]Signal peptides and cleavage sites were described with the method of von Heijne (Nucleic Acids Res., 1986, 14:4683) implemented in EMBOSS (Rice et al., Trends in Genetics, 2000, 16:276-277), and the method of Nielsen et al. (Protein Engineering, 1997, 10:1-6). N-glycosylation sites were predicted using the algorithm of Brunak (Gupta and Brunak, Pac. Symp. Biocomput., 2002, 310-22).

[0326]Functional domains were detected by searching PFAM-Hidden-Markov-Models (version 7.8) (Sonnhammer et al., Nucleic Acids Res., 1998, 26:320-322). Sequences from the PFAM DUF323 seed were obtained from TrEMBL (Bairoch, A. and Apweiler, R., Nucleic Acids Res., 2000, 28:45-48). Multiple alignments and phylogenetic tree constructions were performed with Clustal W (Thompson, J., et al., Nucleic Acids Res., 1994, 22:4673-4680). For phylogenetic tree computation, gap po...

example 3

[0348]FGE Expression Causes Significant Increases in Sulfatase Activity in Cell Lines that Overexpress a Sulfatase

[0349]We wanted to examine the effects of FGE on cells expressing / overexpressing a sulfatase. To this end, HT-1080 cells expressing human sulfatases Iduronate 2-Sulfatase (I2S) or N-Acetylgalactosamine 6-Sulfatase (GALNS) were transfected in duplicate with either a FGE expression construct, pXMG.1.3 (Table 7 and FIG. 4) or a control plasmid, pXMG.1.2 (FGE in antisense orientation incapable of producing functional FGE, Table 7). Media samples were harvested 24, 48, and 72 hours following a 24 hour post-electroporation medium change. The samples of medium were tested for respective sulfatase activity by activity assay and total sulfatase protein level estimated by ELISA specific for either Iduronate 2-Sulfatase or N-Acetylgalactosamine 6-Sulfatase.

TABLE 6Transfected Cell Lines Expressing Sulfatases Used as Substrates forTransfectionCell StrainPlasmidSulfatase Expressed36Fp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Tmaaaaaaaaaa
temperaturesaaaaaaaaaa
volumeaaaaaaaaaa
Login to View More

Abstract

This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.

Description

RELATED APPLICATIONS[0001]This application is a continuation of prior filed, co-pending application Ser. No. 10 / 775,678, filed Feb. 10, 2004, which claims priority under 35 U.S.C. §119(e) from Provisional U.S. Patent Application Ser. No. 60 / 447,747, filed Feb. 11, 2003, and entitled DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES. The contents of each application are hereby expressly incorporated by reference.FIELD OF THE INVENTION[0002]This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.BACKGROUND OF THE INVENTION[0003]Sulfatases are members of a highly conserved gene family, sharing extensive sequence homology (Franco, B., et al., Cell, 1995, 81:...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N9/16C12N15/85C12P21/00A61P17/00A61K38/46A61P3/00A61P25/00A61P19/00C12N15/55C12N5/10A61K38/00A61K38/16C12N9/02
CPCA61K38/00A61K48/0066C12N9/0071A61K2039/53A61K38/44A61K38/465C12N9/0051C12N9/16C12Y108/99C12Y301/06013A61P15/00A61P15/08A61P17/00A61P19/00A61P19/08A61P25/00A61P25/02A61P3/00A61P43/00Y02A50/30
Inventor VON FIGURA, KURTSCHMIDT, BERNHARDDIERKS, THOMASHEARTLEIN, MICHAEL W.BALLABIO, ANDREACOSMA
Owner SHIRE HUMAN GENETIC THERAPIES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products